Overview
InGel Therapeutics is developing innovative cell-based therapy to bring back light to patients who suffer from all forms of retinal degeneration. Our lead program, IGT001, is a mutation-agnostic approach to Retinitis Pigmentosa, with future expansion opportunities including dry AMD and Glaucoma.